tldrdailynews.com logo

Pancreatic cancer drug duo shows durable responses, advancing to Phase 3

1 min read
Source: statnews.com
Pancreatic cancer drug duo shows durable responses, advancing to Phase 3
Photo: statnews.com
TL;DR

A two-drug combo of Tango Therapeutics’ vopimetostat and Revolution Medicines’ daraxonrasib produced durable responses in the large majority of pancreatic cancer patients in an early-stage trial, prompting Tango to advance the approach to a Phase 3 study.

Topics:businesshealth#combination-therapy#early-stage-trial#health#pancreatic-cancer#revolution-medicines#tango-therapeutics
Share this article
  1. Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate  statnews.com
  2. Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer  Yahoo Finance
  3. ‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response  BioSpace
  4. 🔎 Under the Radar: Tango Stock Climbs on Positive Pancreatic Cancer Data  WSJ
  5. Tango Soars as Study Shows Its Drug Can Help Shrink Tumors  Bloomberg.com

Want the full story? Read the original reporting

Read on statnews.com